Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides

Clinical Immunology and Immunopathology

Volumn 85, Issue 3, 1997, Pages 265-272

  Sato, Takami ^a   Bullock, Timothy N J ^a   Eisenlohr, Laurence C ^a   Mastrangelo, Michael J ^a   Berd, David ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENOL; GAMMA INTERFERON; HAPTEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELANOMA VACCINE; PEPTIDE;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MELANOMA; PRIORITY JOURNAL; SPECTROMETRY; T LYMPHOCYTE;

EID: 0031392566     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1997.4419     Document Type: Article

References (23)

1. Brichard V., Van Pel A., Wölfel C., De Plaen E., Lethe B., Coulie P., Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:1993;489-495.
2. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P., Rivoltini L., Yannelli J., Apella A., Rosenberg S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:1994;347-352.
3. Van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643-1647.
4. Zhai Y., Yang J. C., Kawakami Y., Spiess P., Wadsworth S. C., Cardoza L. M., Couture L. A., Smith A. E., Rosenberg S. A. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol. 156:1996;700-710.
5. Mukherji B., Chakraborty N. G., Yamasaki S., Okino T., Yamase H., Sporn J. R., Kurtzman S. K., Ergin M. T., Ozols J., Meehan J. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA. 92:1995;8078-8082.
6. Berd D., Murphy G., Maguire H. C. Jr., Mastrangelo M. J. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res. 51:1991;2731-2734.
7. Berd D., Maguire H. C. Jr., Mastrangelo M. J. Treatment of human melanoma with a hapten-modified autologous vaccine. Ann. NY Acad. Sci. 690:1993;147-152.
8. Berd D., Maguire H. C. Jr., Schuchter L. M., Hamilton R., Hauck W. W., Sato T., Mastrangelo M. J. Autologous, hapten-modified melanoma vaccine as post-surgical adjuvant treatment after resection of nodal metastases. J. Clin. Oncol. 15:1997;2359-2370.
9. Berd D., Maguire H. C. Jr., Mastrangelo M. J., Murphy G. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunol. Immunother. 39:1994;141-147.
10. Lattime E. C., Mastrangelo M. J., Bagasra O., Li W., Berd D. Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol. Immunother. 41:1995;151-156.
11. Sensi M., Farina C., Maccalli C., Lupetti R., Nicolini G., Anichini A., Parmiani G., Berd D. Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. J. Clin. Invest. 99:1997;710-717.
12. Sato T., Maguire H. C. Jr., Mastrangelo M. J., Berd D. Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine. Clin. Immunol. Immunopathol. 74:1995;35-43.
13. Morgan A. C. Jr., Galloway D. R., Reisfeld R. A. Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma. 1:1981;27-36.
14. Miller S. D., Claman H. N. The induction of hapten-specific T cell tolerance by using hapten-modified lymphoid cells. I. Characteristics of tolerance induction. J. Immunol. 117:1976;1519-1526.
15. Rötzschke O., Falk K., Wallny H. J., Faath S., Rammensee H. G. Characterization of naturally occurring minor histocompatibility peptides inducing H-4 and H-Y. Science. 249:1990;283-287.
16. Jackson G. E. D., Young N. M. The dinitrophenyl group as a selective label in high-performance liquid chromatography of peptides. Anal. Biochem. 162:1987;251-256.
17. von Bonin A., Martin S., Plaga S., Hebbelmann S., Weltzien H. U. Purified MHC class I molecules present hapten-conjugated peptides to TNP/H-2Kb-specific T cell hybridomas. Immunol. Lett. 35:1993;63-68.
18. Martin S., von Bonin A., Fessler C., Pflugfelder U., Weltzien H. U. Structural complexity of antigenic determinants for class I MHC-restricted, hapten-specific T cells: Two qualitatively differing types of H-2Kb-restricted TNP epitopes. J. Immunol. 151:1993;678-687.
19. von Bonin A., Ortmann B., Martin S., Weltzien H. U. Peptide-conjugated hapten groups are the major antigenic determinants for trinitrophenyl-specific cytotoxic T cells. Int. Immunol. 4:1992;869-874.
20. Martin S., Ortmann B., Pflugfelder U., Birsner U., Weltzien H. U. Role of hapten-anchoring peptides in defining hapten-epitopes for MHC-restricted cytotoxic T cells: Cross-reactive TNP-determinants on different peptides. J. Immunol. 149:1992;2569-2575.
21. Weltzien H. U., Hebbelmann S., Pflugfelder U., Ruh H., Ortmann B., Martin S., Iglesias A. Antigen contact sites in class I major histocompatibility complex-restricted, trinitrophenyl-specific T cell receptors. Eur. J. Immunol. 22:1992;863-866.
22. Kempkes B., Palmer E., Martin S., von Bonin A., Eichmann K., Ortmann B., Weltzien H. U. Predominant T cell receptor gene elements in TNP-specific cytotoxic T cells. J. Immunol. 147:1991;2467-2473.
23. Kim B. S., Jang Y. S. Constrains in antigen processing result in unresponsiveness to a T cell epitope of hen egg lysozyme in C57BL/6 mice. Eur. J. Immunol. 22:1992;775-782.